- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00110305
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
11 de junio de 2014 actualizado por: Tibotec Pharmaceuticals, Ireland
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This is a randomized (the study medication is assigned by chance), active controlled (participants are assigned to either a recognized effective treatment or the study medication) study.
This study consists of 3 phases: screening phase (4 weeks), treatment phase (96 weeks), and follow up phase (4 weeks).
In the treatment phase, participants will be randomly assigned to 1 of the 4 treatment groups: (1) TMC278 25 mg, (2) TMC278 75 mg, (3) TMC278 150 mg, or (4) efavirnez (control group); along with investigator selected 2 non-nucleoside reverse transcriptase inhibitor (NRTIs) until Week 96.
TMC278 will be assigned by double-blinded fashion (participant and investigator are not aware of the TMC278 dose what participants will receive) and efavirnez will be assigned by open-label fashion (all people know what treatment participants will receive).
After Week 96, 3 optional open-label (all people know the identity of the intervention) extension periods will be conducted to collect long term safety and effectiveness data of TMC278.
3 optional extension periods are: first optional extension period (all participants will receive TMC278 75 mg + 2 NRTIs from Week 96 to Week144); second optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 144 to Week 240); and third optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 240 until TMC278 is commercially available).
Participants on efavirenz group will have the option to continue on efavirenz + 2 NRTIs until the total treatment duration of 240 weeks.
Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, physical examination, and vital signs which will be monitored throughout the study.
The maximum duration of the study will be 104, 152, or 248 weeks, plus the optional third extension period.
Tipo de estudio
Intervencionista
Inscripción (Actual)
368
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Berlin, Alemania
-
Freiburg, Alemania
-
Köln, Alemania
-
München, Alemania
-
-
-
-
-
Buenos Aires, Argentina
-
Rosario, Argentina
-
-
-
-
-
Wien, Austria
-
-
-
-
-
Campinas, Brasil
-
Curitiba, Brasil
-
Pinheiros, Brasil
-
Rio De Janeiro, Brasil
-
Sao Paulo, Brasil
-
-
-
-
California
-
Beverly Hills, California, Estados Unidos
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
-
-
Florida
-
Orlando, Florida, Estados Unidos
-
Tampa, Florida, Estados Unidos
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos
-
-
New York
-
Stony Brook, New York, Estados Unidos
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos
-
-
Texas
-
Addison, Texas, Estados Unidos
-
-
Washington
-
Seattle, Washington, Estados Unidos
-
-
-
-
-
Kazan, Federación Rusa
-
Moscow, Federación Rusa
-
Moscow N/A, Federación Rusa
-
Nizhny Novgorod, Federación Rusa
-
Saint-Petersburg, Federación Rusa
-
St Petersburg, Federación Rusa
-
Volgograd, Federación Rusa
-
-
-
-
-
Paris, Francia
-
Paris Cedex 10, Francia
-
Paris Cedex 12, Francia
-
Tourcoing, Francia
-
-
-
-
-
Ciudad De Mexico, México
-
-
-
-
-
Beijing, Porcelana
-
-
-
-
-
San Juan, Puerto Rico
-
-
-
-
-
London, Reino Unido
-
Manchester, Reino Unido
-
-
-
-
-
Bloemfontein, Sudáfrica
-
Cape Town, Sudáfrica
-
Johannesburg, Sudáfrica
-
-
-
-
-
Bangkok, Tailandia
-
Chiang Mai, Tailandia
-
Khon Kaen, Tailandia
-
-
-
-
-
Kampala, Uganda
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Documented human immunodeficiency virus type 1 (HIV-1) infection
- Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors
- HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening
- Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening
- Sensitivity to investigator selected nucleosides, at screening
Exclusion Criteria:
- Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness
- Known or suspected acute (primary) HIV-1 infection
- Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection
- Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening
- Pregnant or breastfeeding females
- Not agree to protocol-defined effective use of contraception
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TMC278 25 mg
Participants will receive TMC278 25 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
TMC278 25 mg tablet will be administered once daily.
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Otros nombres:
|
|
Experimental: TMC278 75 mg
Participants will receive TMC278 75 mg once daily up to Week 144.
Later on, participants will receive TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Otros nombres:
TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
|
|
Experimental: TMC278 150 mg
Participants will receive TMC278 150 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Otros nombres:
TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
|
|
Comparador activo: Efavirenz
Participants will receive efavirenz 600 mg once daily up to Week 96.
Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Otros nombres:
Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Periodo de tiempo: Week 48
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 48
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Periodo de tiempo: Week 96
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Periodo de tiempo: Week 96
|
The analysis is based on the last observed viral load data within the Week 96 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Periodo de tiempo: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Periodo de tiempo: Week 240
|
The analysis is based on the last observed viral load data within the Week 240 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Periodo de tiempo: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 96
Periodo de tiempo: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 96
Periodo de tiempo: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 240
Periodo de tiempo: Baseline (Day 1 of Week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 240
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 240
Periodo de tiempo: Baseline (Day 1 of week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of week 0) to Week 240
|
|
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
Periodo de tiempo: Week 240
|
Virologic failure for the resistance determinations was defined as a viral load greater than 0.5 log10 copies /mL above the nadir with a minimum of 500 copies/mL.
For this study, treatment-emergent mutations (for at least one treatment) are presented as Resistance associated mutation (RAMs): i) Non-nucleotide reverse transcriptase inhibitor (NNRTI) RAMs, ii) Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).
|
Week 240
|
|
Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278
Periodo de tiempo: Up to Week 96
|
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Trough Plasma Concentration (Ctrough) for TMC278
Periodo de tiempo: Up to Week 96
|
For each participant, a single value for trough (i.e.
predose) plasma concentration (Ctrough) of TMC278 was estimated from a population pharmacokinetic model, based on samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles
Periodo de tiempo: Up to Week 96
|
Quartile 1, 2, 3 and 4 of AUC24h means the quartile with the lowest 25%, 26-50%, 51-75% and the highest 25% of AUC24h values, respectively, irrespective of the different doses of TMC278.
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
Virologic response was calculated by time to loss of virologic response (TLOVR) algorithm.
|
Up to Week 96
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de junio de 2005
Finalización primaria (Actual)
1 de diciembre de 2011
Finalización del estudio (Actual)
1 de diciembre de 2011
Fechas de registro del estudio
Enviado por primera vez
5 de mayo de 2005
Primero enviado que cumplió con los criterios de control de calidad
5 de mayo de 2005
Publicado por primera vez (Estimar)
6 de mayo de 2005
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
25 de junio de 2014
Última actualización enviada que cumplió con los criterios de control de calidad
11 de junio de 2014
Última verificación
1 de junio de 2014
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Enfermedades del sistema inmunológico
- Enfermedades de virus lentos
- Infecciones por VIH
- Síndrome de inmunodeficiencia adquirida
- Síndromes de deficiencia inmunológica
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes Anti-VIH
- Agentes antirretrovirales
- Inhibidores de enzimas del citocromo P-450
- Inductores de enzimas de citocromo P-450
- Inductores de citocromo P-450 CYP3A
- Inductores de citocromo P-450 CYP2B6
- Inhibidores del citocromo P-450 CYP2C9
- Inhibidores del citocromo P-450 CYP2C19
- Inhibidores de la transcriptasa inversa
- Efavirenz
- Rilpivirina
Otros números de identificación del estudio
- CR006760
- TMC278-C204 (Otro identificador: Tibotec Pharmaceuticals, Ireland)
- R278474-C204 (Otro identificador: Tibotec Pharmaceuticals, Ireland)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .